Search results
Launching an effective bird flu vaccine quickly could be tough, scientists warn
NPR· 17 hours ago"There's a lot of gaps in our preparedness response. We don't have prioritization strategy on who to...
Free Comic Book Day 2024 List & Info You Need to Know
SuperHeroHype via Yahoo News· 8 hours agoAnnually held on the first Saturday in May, Free Comic Book Day is a major event for comic fans...
Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 12 hours agoCerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript May 2, 2024 Cerus Corporation...
Magazine: Anticipation rises for RSV rollout as positive data emerges
Pharmaceutical Technology via Yahoo Finance· 2 days agoIn this issue: Following the RSV therapy and vaccine rollout, understanding molecular glues, using...
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoEmergent BioSolutions Inc. (NYSE:EBS) Q1 2024 Earnings Call Transcript May 1, 2024 Emergent...
Free Comic Book Day is this weekend, so here's all the free comics you can grab
Mashable· 19 hours agoThere's something for everyone.
AI Supercharges Fentanyl Production And Distribution, Study Finds
Forbes· 7 days agoA team of global experts in AI and synthetic chemistry have just published their research into AI’s...
Earnings call: Cerus Corporation sees growth with INTERCEPT RBCs trial success
Investing.com· 21 hours agoCerus Corporation (NASDAQ: CERS ) has announced positive outcomes from its Phase 3 ReCePI clinical...
EverGlade Consulting Welcomes New Managing Director, Joe Larsen
The Parsons Sun· 2 days agoEverGlade Consulting is pleased to announce the appointment of Dr. Joe Larsen as Managing Director, effective April 2024. Dr. Larsen brings with him a rich background in biomedical research ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 20 hours agoAllschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that